Respiratory Syncytial Virus (RSV) Vaccine (GSK 212494)

A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults above.

Register Today!

Trial Information

Start DateJune 2021
End DateTBD
Trial DurationTBD
Number of Visits8 visits
Lead CRCSuzanne Fleming
StatusOngoing

For additional information
on this trial contact:

Phone705-566-0005